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Introduction
Central nervous system (CNS) can be involved during 
several autoimmune systemic vasculitis. Neurological 
and neuropsychiatric manifestations are still object 
of debate in literature. It has been estimated that the 
prevalence of CNS involvement during vasculitis 
may vary from 2.5 to 60%, depending on the reported 
experiences and tests of evaluation.[1-3]
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Abstract
Background: The diagnosis of  vasculitis in the brain remains a quite difficult achievement. To the best of  our knowledge, there is 
no imaging method reported in literature which is capable of  reaching to a diagnosis of  vasculitis with very high sensitivity. Aim: 
The aim of  this study was to determine whether perfusion brain single photon emission computed tomography (SPECT) can be 
usefully employed in monitoring the treatment of  vasculitis, allowing treating only potentially responder patients and avoiding the 
side effects on patients who do not respond. Materials and Methods: Twenty patients (two males and 18 females) suffering from 
systemic lupus erythematosus (SLE; n = 5), Behcet’s disease (BD; n = 5), undifferentiated vasculitis (UV; n = 5), and Sjogren’s 
syndrome (SS; n = 5) were included in the study. All patients underwent a wide neurological anamnestic investigation, a complete 
objective neurological examination and SPECT of  the brain with 99mTc-hexamethyl-propylene-aminoxime (HMPAO). The brain 
SPECT was then repeated after appropriate medical treatment. The neurological and neuropsychiatric follow-up was performed 
at 6 months after the start of  the treatment. Results: Overall, the differences between the scintigraphic results obtained after and 
before the medical treatment indicated a statistically significant increase of  the cerebral perfusion (CP). In 19 out of  200 regions 
of  interest (ROI) studied, the difference between pre- and post treatment percentages had negative sign, indicating a worsening of  
CP. This latter event has occurred six times (five in the same patients) in the UV, 10 times (eight in the same patients) in the SLE, 
never in BD, and three times (two in the same patient) in the SS. Conclusion: The reported results seem to indicate the possibility 
of  identifying, by the means of  a brain SPECT, responder and nonresponder (unchanged or worsened CP) patients, affected by 
autoimmune vasculitis, to the therapy.
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This is particularly true in cases of early impairment in 
which a mild cognitive impairment (MCI) can be the 
only symptom.[4,5] Often CNS involvement can precede 
clinical diagnosis by many years and determine an 
underestimation of other neurological and/or systemic 
diseases.[6] Moreover, prompt diagnosis and treatment 
could significantly ameliorate neurological symptoms 
and improve prognosis. The most commonly applied 
radiologic techniques, such as computed tomography 
(CT) and magnetic resonance imaging (MRI), are not 
enough sensitive to reflect the pathophysiological 
changes happening in CNS during vasculitis. Also 
cerebral angiography in characterized by a low 
sensitivity and is burdened by some risk.[7,8]
Therefore, more sensitive diagnostic techniques which are 
able to asses CNS subclinical involvement is advisable, 
especially for patients with atypical neurologic and 
neuropsychiatric manifestations or patients at a very 
early stage of disease. According to literature,[9,10] single 
photon emission computed tomography (SPECT) is more 
sensitive than MRI in revealing damage in CNS related 
to vasculitis; moreover, SPECT seems able to provide 
additional information during follow-up, especially in the 
monitoring phase of the disease severity and treatment.[11-17]
The purpose of this study was to determine whether 
brain SPECT using 99mTc-hexamethyl-propylene-
aminoxime (HMPAO) as radiocompound can be usefully 
employed in monitoring the treatment of vasculitis, 
allowing selection patients with high likelihood to obtain 
benefi t from specifi c treatment, and at the same time 
avoid side effects on nonresponder patients.
Materials and Methods
Patients
The present research has been approved by our 
Institutional Ethics Committee. Moreover, all patients 
gave their informed consent before entering the study.
The study was performed on 20 prospectively and 
consecutive enrolled patients, affect by autoimmune 
vasculitis and adopting the following inclusion criteria:
1. Age less than 45 years;
2. negative brain MRI;
3. presence of  nonspecif ic  neurological  and 
neuropsychiatric symptoms (headache, disorders’ 
attention, and so forth);
4. no previous treatments (corticosteroids) for at least 
3 months, and
5. time from disease diagnosis less than 5 years. 
On this basis, 20 patients (2 males and 18 females) 
were recruited: Five were affected by systemic lupus 
erythematosus (SLE), fi ve by Behcet’s disease (BD), fi ve 
by undifferentiated vasculitis (UV), and fi ve by Sjogren’s 
syndrome (SS). The mean age of patients was 36.3 years 
(standard deviation (SD) ± 10.6 years) and the mean 
disease duration was 1.77 years (SD ± 0.83).
Clinical, psychiatric, and neuropsychological 
evaluation
All patients underwent neurological history and physical 
examination. Moreover, various serological tests were 
taken into account.
Specific subjective symptoms were evaluated with 
appropriate tools as presented in Table 1.
The Second Edition of the International Classifi cation of 
Headache Disorders (ICHD-II) was applied to establish 
a headache diagnosis and score.[18]
The psychiatric assessment was based on history and 
clinical interview focused on:
a. Current or past psychopathological disorders;
b. structure of the personality; and
c. signs and symptoms of reactive disorders to chronic 
illness, steroids, or disease-modifying (biological) 
therapies.
Moreover, all patients underwent a global screening 
test using the Clinical Global Impression Severity Scale 
(CGIs) and following specifi c tests to detect possible 
behavioral correlates of executive functions: Beck 
Depression Scale II (BDII), State-Trait Anxiety Inventory 
Y1 and Y2 (STAY), and Apathy Evaluation Scale (AES). 
Basal cognitive evaluation was evaluated by Mini-Mental 
State Examination (MMSE) for cognitive effi ciency and 
Brief Intelligence Test (TIB) for intelligent quotient (IQ). 
Regardless of screening tests, all patients underwent a 
complete neuropsychological assessment in order to 
explore the main cognitive domains by means of:
a. Verbal span;
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Table 1: Mean and standard deviation (SD) of the 
percentage of the maximum count rate registered 
on the encephalon, calculated for all the region of 
interest selected: Comparison between the values 
obtained before and aft er the medical treatment
??? UV SLE BD SS
Mean ± SD 
(pretreatment) 59±6 59±4 60±5 55±2
Mean ± SD 
(post treatment) 63±5 62±5 65±4 57±2
T 6.259 5.03 10.122 7.52
P <0.001 <0.001 <0.001 <0.001
SLE = Systemic lupus erythematosus, BG = Behcet’s disease, UV = 
Undifferentiated vasculitis, SS = Sjogren’s syndrome
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b. Trail Making Test (parts A & B);
c. Rey Auditory Verbal Learning Test;
d. the Rey-Osterrieth Complex Figure Test (ROCF) (with 
immediate and delayed recall);
e. Test of Weights and Measures Estimation (STEP);
f. Test of Phonological Verbal Fluency/Semantics;
g. Corsi Block Tapping Test; Tower of London - Italian 
version;
h. Token Test; and
i. Aachener Aphasie Test. Raw scores have been 
adjusted for age, sex, and education parameters.
Scintigraphic studies
All patients were prescribed to suspend the intake 
of coffee, alcohol, and tobacco at least 48 h before 
scintigraphic examination. All were evaluated by brain 
SPECT using 99mTc-HMPAO as radiocompound. 
99mTc-HMPAO is a lipophilic radiopharmaceutical 
used for the assessment of cerebral perfusion (CP). 
This product was prepared using a commercial kit 
(Ceretec®, GE Healthcare Italy, Milan) prepared adding 
HMPAO in 740 ÷ 1,110 MBq of sodium pertechnetate 
diluted in 2 ml of saline. The radiopharmaceutical was 
administered to patients intravenously 15 min after its 
preparation. After injection, the patient was placed on 
the bed of the gamma-camera and kept away from light 
and sound stimulation for 15 min. Forty minutes later, 
patient head was fi xed in the orbitomeatal line position 
by a hemicylindrical plastic head-holder to maintain 
immobilization during acquisition.
Brain SPECT was performed by a dual-head, large fi eld 
of view gamma camera (Infi nia®, GE Healthcare Italy, 
Milan) equipped with a couple of high-resolution, low-
energy parallel holes collimators.
Acquisition was performed on a circular orbit of 360°, 
applying the smallest possible radius, with sampling 
angle of about 3° and a time of 25 s per projection, 
with acquisition matrix 128 × 128. The energy window 
was positioned on the peak of 99mTc (140 keV ± 10%). 
Image reconstruction was performed using filtered 
back projection with a Butterworth fi lter and a ramp 
fi lter. Transaxial, coronal, and sagittal sections, oriented 
along the orbitomeatal line, were than generated. 
Image analysis was performed using a specifi c software 
(Neurogam®, GE Healthcare Italy, Milan) capable of 
providing for each cerebral area the mean and the SD 
of the counts recorded expressed as a percentage of the 
maximum count rate registered on the encephalon. Ten 
regions of interest (ROI) were selected for each patient, 
corresponding to the entire cortex and the parietal, 
temporal, frontal, and occipital regions. The brain SPECT 
was then repeated after appropriate medical treatment 
and the data of the second test were compared with those 
AQ3
of the fi rst, for each group of pathology, subtracting the 
pretreatment values luesent va post-treatment.
Statistical methods
Mean values were statistically compared by t-test and 
differences in number of groups’ values by chi-square 
test. P - value less than 0.05 were statistically considered 
as signifi cant. Version 17.0 of Statistical Package for 
Social Sciences (SPSS) software (SPSS Inc, Chicago, 
Illinois, USA, 2008) was used.
Results
Clinical, psychiatric and neuropsychological 
evaluation
According to imaging and neurological evaluations, 
nonfocal and subclinical CNS involvement was 
observed in all patients. Particularly, headache was 
the most frequent observed symptom occurring in 
14 patients (70%). Cognitive impairment was observed 
in 11 patients (55%); fi ve patients (25%) had sensitive 
disorders and pain, seven (35%) had fatigue, eight (40%) 
had mood disorders, and only one patient (0.5%) had 
seizures [Figure 1]. None of the patients showed focal 
neurological defi cits. Headache was defi ned on the basis 
of the ICHD-II diagnostic criteria. The most frequently 
observed headache (71.4% of the patients, n = 10) satisfi ed 
ICHD-II criteria for migraine without aura (MWO) with 
generally unilateral pain; oppressive-throbbing type 
and moderate-to-severe intensity; worsened by physical 
activity; and associated with nausea, photophobia, and 
phonophobia. From the cognitive point of view, 55% 
(n = 11) of the patients enrolled presented an impairment 
of at least one neuropsychological tests used. Between 
the explored functions, the most compromised were 
executive functions and verbal memory, signifi cantly 
altered in 66.7% (n = 8) patients. On the basis of 
AQ4
Figure 1: Percentage of central nervous system manifestations 
occurred in our patients
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psychiatric evaluation, 40% (n = 8) of patients showed 
a score higher than 14 on the BDI-II as in depressive 
disorder, while STAY Y1 and Y2 were pathological in 
15% (n = 3) and 0.5% (n = 1) of cases, respectively. A high 
score on the AES was observed in 30% of patients (n = 6).
After the execution of the clinical evaluations and the 
fi rst scintigraphy, all patients started treatment on the 
basis of rheumatologist antivasculitis prescription. 
All patients received corticosteroids, at doses ranging 
from 5 to 25 mg/day. Five patients (25%) were given 
also ticlopidine, fi ve (25%) colchicines, and eight (40%) 
chloroquine.
The neurological and neuropsychiatric follow-up was 
performed at 12 months after the beginning of the 
treatment. At this time, fi ve patients (25%) (two patients 
with UV, two patients with SLE, and one patients with 
SS) showed worsening in clinical and neuropsychiatric 
evaluations in spite of treatment, whereas the other an 
amelioration.
Scintigraphic studies
In most cases, the differences between the percentages 
(of the maximum count rate registered on the brain) 
calculated after and before medical treatment by means 
of ROI method had positive signs, indicating an increase 
of the CP. In 19 of the 200 ROIs studied, the difference 
between pre- and post treatment percentages had negative 
sign, indicating a worsening of CP. This latter event has 
occurred six times (fi ve in the same patients) in the UV 
[Figure 2], 10 times (eight in the same patients) in the SLE 
[Figure 3], never in BD [Figure 4], and three times (two in 
the same patient) in the SS [Figure 5]. The number of areas 
that showed no variations between the SPECT performed 
before and after the treatment was as follows: Five areas 
in UV, seven areas in SLE, 0 in BD, and 6 in SS.
The scintigraphic results are summarized in Table 1, 
which shows the overall means and SDs calculated on 
the areas of interest for each disease. In the same table 
can be seen as the differences between the values  e 
values e values mea those obtained after treatment are 
statistically signifi cant.
Discussion
Vasculitis is an inflammation of the walls of blood 
vessels. This infl ammatory process can occur without 
known cause (primary vasculitis), or secondarily as a 
result of an infectious process, or in combination with 
other conditions. In vasculitis, the immune system is 
overactive and mistakenly recognizes the blood vessel 
cells as foreign and dangerous, so it attacks them as they 
were a bacterium or a virus. It is not always clear why 
this happens, but an infection, certain types of cancer 
and immune system disorders, certain medications, or an 
allergic reaction often act as a trigger. The infl ammatory 
process leads to changes in the walls of blood vessels, 
narrowing the lumen of the vessels and reducing the 
amount of blood that reaches tissues and organs. In some 
cases, in an affected vessel may occur a thrombus or a 
granuloma, which obstructs the blood fl ow. Other times, 
instead of narrowing the vessel, vasculitis weakens the 
blood vessel, resulting in the occurrence of an aneurysm.
The use of brain 99mTc-HMPAO SPECT in the early 
diagnosis of vasculitis has been widely reported in 
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Figure 2: Percentage increase of the radiopharmaceutical uptake 
after medical treatment in patients with undifferentiated vasculitis. 
RC = Right cortex, LC = Left cortex, RFL = Right frontal lobe, 
LFL = Left frontal lobe, ROL = Right occipital lobe, LOL = Left 
occipital lobe, RPL = Right parietal lobe, LPL = Left parietal lobe, 
RTL = Right temporal lobe, LTL = Left temporal lobe
AQ5 Figure 3: Percentage increase of the radiopharmaceutical uptake 
after medical treatment in patients with systemic lupus erythematosus 
(SLE) RC = Right cortex, LC = Left Cortex, RFL = Right frontal 
lobe, LFL = Left frontal lobe, ROL = Right occipital lobe, LOL = Left 
occipital lobe, RPL = Right parietal lobe, LPL = Left parietal lobe, 
RTL = Right temporal lobe, LTL = Left temporal lobe
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the literature since the 1990s. In 1996, Meusser et al.,[19] 
studied 40 patients affected by systemic vasculitis, 
finding SPECT abnormalities both in patients with 
major (motoric or sensible defects) or mild (headache or 
cognitive disorders) neuropsychiatric symptoms both in 
patients with none of these symptoms.
Similar results were obtained, some years after, in 
another study carried out in 78 patients affected by 
SLE.[20] In that study, patients were divided into two 
groups: Group 1 including 48 cases with definite 
neuropsychiatric symptoms and Group 2 consisting of 
30 cases having no neuropsychiatric symptoms. Ninety 
percent of the patients of Group 1 and 20% of those of 
Group 2 showed brain hypoperfusion areas.
99mTc-HPAO brain SPECT was found to be useful 
for detecting subclinical perfusion abnormalities also 
in patients affected by BD.[21] In these study, SPECT 
revealed abnormalities in 16 out of 25 patients (64%) 
suffering from headaches alone, not accompanied by 
abnormal signs on neurological examination.
In patients with BD submitted to SPECT because of 
neuropsychiatric signs/symptoms, revealed reduced 
perfusion in the watershed areas of the frontal lobes 
whose severity was correlated with the severity of 
cognitive dysfunction.[22]
Lass et al.,[23] studied with 99mTc-HMPAO brain 
SPECT 21 patients affected by SS and they found a high 
rate of alterations in cerebral blood fl ow in SS, both 
psychoneurologically symptomatic and asymptomatic. 
Perfusion deficits were seen in 17 of 21 patients 
AQ6
AQ7
(80.9%) with SS: 13/15 symptomatic (86.6%) and 4/6 
asymptomatic (66.6%).
MRI is a very useful tool in the study of brain disease and 
it is for this reason that the experimental design of many 
studies is based on a comparison between the results of 
this examination and those of brain SPECT. In 1997, Lin 
et al., studied 72 SLE patients divided into three groups: 
Group 1 with definite neuropsychiatric disorders, 
Group 2 with minor neuropsychiatric disorders, and 
Group 3 without any of these disorders. SPECT results 
were abnormal in all patients of Group 1, in 84.6% of 
patients of Group 2, and in 13% of patients of Group 3. 
MRI resulted less sensitive, being normal in 27.3% of 
patients with definite neuropsychiatric disorders.[24] 
Other authors had already reported a poor correlation of 
SPECT with MRI, on numerically inferior series, arguing 
that SPECT was the most sensitive exam.[10]
A comparison between SPECT and MRI was performed 
in 40 patients affected by SLE, with active and inactive 
CNS manifestations; using, as brain perfusion agent, 
99mTc-ethyl-cysteinate-dimer (ECD).[25] The authors 
found a signifi cant hypoperfusion in frontal, parietal, and 
temporal lobes in patients with active CNS involvement 
when compared with patients with past history of CNS 
involvement or with healthy volunteers. These perfusion 
abnormalities occurred in areas without structural 
abnormalities on MRI.
In 2008, Castellino et al., studied 107 patients with SLE 
in order to assess the relationship between clinical 
picture and neuroimaging in patients affected by SLE 
with and without neuropsychiatric involvement.[26] 
Since normal fi ndings contemporarily detected by 
AQ6
Figure 4: Percentage increase of the radiopharmaceutical uptake after 
medical treatment in patients with Behcet’s disease RC = Right cortex, 
LC = Left Cortex, RFL = Right frontal lobe, LFL = Left frontal lobe, 
ROL = Right occipital lobe, LOL = Left occipital lobe, RPL = Right 
parietal lobe, LPL = Left parietal lobe, RTL = Right temporal lobe, 
LTL = Left temporal lobe
AQ5
Figure 5: Percentage increase of the radiopharmaceutical uptake after 
medical treatment in patients with Sjogren’s syndrome RC = Right 
cortex, LC = Left Cortex, RFL = Right frontal lobe, LFL = Left 
frontal lobe, ROL = Right occipital lobe, LOL = Left occipital lobe, 
RPL = Right parietal lobe, LPL = Left parietal lobe, RTL = Right 
temporal lobe, LTL = Left temporal lobe
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SPECT and MRI were rarely observed in patients 
with neuropsychiatric involvement, the authors feel 
that combining these two techniques is more useful 
than the two techniques alone in the assessment of 
neuropsychiatric involvement.
More recent experiences seem to confi rm that SPECT is 
more sensitive than MRI in revealing the involvement 
of the CNS in some autoimmune diseases. A total of 
24 patients with BD and signs or symptoms of CNS 
involvement were enrolled in a study which contemplated 
the execution of SPECT with 99mTc-HMAPO, CT, and 
MRI. SPECT showed impaired perfusion in all cases 
with neurological complaints, while brain MRI and CT 
images were normal or nonspecifi c in all cases.[27] In the 
same study, eight patients underwent to a clinical and 
instrumental follow-up in order to assess the effect of 
therapy. The authors concluded that brain SPECT is also 
a useful modality for evaluating the effects of treatment 
and disease monitoring.
The utility of SPECT in monitoring the treatment of 
vasculitis has been reported since 1992 and even in this 
kind of application, this test seems to provide better 
results compared to MRI. However, most of the studies 
are case reports,[11,12] retrospective studies,[13] or small 
series of patients.[14-17]
From the above, it can be argued that SPECT is the 
most sensitive investigation in evaluating the flow 
alterations in cerebral vasculitis in patients with minor 
neuropsychiatric disorders or even in patients without 
any of these disorders, since it seems able to reveal 
changes in cerebral blood fl ow in patients with negative 
MRI. Furthermore, it is considered an objective tool for 
measuring the effect of therapy. On this basis was built 
our experimental design, which is focused on the study 
of changes in cerebral blood fl ow after therapy in patients 
with negative basal MRI.
The SPECT results clearly show an improvement of 
blood fl ow after therapy in large part of the studied 
cerebral areas [Figures 6 and 7]. The magnitude of 
this improvement is quite similar, in percentage terms, 
in all the studied diseases (5% in BD, 4% in UV, 3% in 
SLE, and 2% in SS) and corresponds to an effective partial 
reduction of clinical symptoms.
Similar results have already been reported in the 
literature,[12-17] and the present study constitutes only 
a confi rmation obtained with a prospective approach 
and in a suffi cient number of patients (considering that 
these diseases are relatively rare) with a relatively low 
disease duration. The information resulting from the 
analysis of the cases characterized by a deterioration 
of cerebral blood fl ow after treatment, however, seems 
more interesting. In fact, our fi ndings reveal that most of 
the brain areas with a worsening of the blood fl ow after 
therapy are concentrated in some patients for each group 
of pathology. In a patient affected by UV, CP decreased 
in fi ve areas after therapy and remained unchanged in 
three areas. In the group of SLE, eight areas of decreased 
CP after therapy and two area without valuable changes 
were found in a patient; while in another case, two 
areas showed a decreased CP and fi ve areas remained 
unchanged. Similar results were found in a patients 
suffering from SS (two cerebral areas with a reduction 
of CP after therapy and fi ve areas unchanged). These 
scintigraphic results completely agree with the clinical 
worsening observed in all the above mentioned four 
patients, in which the majority of cerebral areas did not 
show any improvement of CP after therapy.
In another case of SS characterized by a stable clinical 
picture, only one area showed a worsening CP, while one 
area did not show signifi cant changes. The interpretation 
of this result seems more problematic. This mismatch 
between scintigraphy and clinical findings can be 
explained in at least two ways:
a b
Figure 6: Patient affected by Behcet’s disease. Sagittal reconstructions. 
(a) Basal SPECT and (b) = SPECT after 1 year therapy (colchicine). 
Signifi cant improvement of cerebral blood fl ow associated with 
regression of the clinical symptoms was noted. SPECT = Single 
photon emission computed tomography
a b
Figure 7: Transaxial reconstruction of brain 99mTc-HMPAO SPECT 
in a patient affected by SLE pre- (a) and posttreatment (b). After 
therapy, the patient developed a worsening of cerebral perfusion 
and clinical symptoms (headache, tingling, and memory defi cits). 
HMPAO = Hexamethyl-propylene-aminoxime
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1. The scintigraphic worsening is too small (only one 
area) and is not suffi cient to cause effects on the 
overall clinical picture; and
2. The scintigraphic result underestimates the actual 
condition of CP.
Taking into account the second hypothesis, it is 
reasonable to assume an underestimation also 
in the remaining areas that show, wrongly, an 
improved CP which instead is worsened or stable. 
If so, however, the clinical picture should be worse 
and not stable, given that, as shown by the results 
reported above, there is some correlation between 
the results of SPECT and clinical symptoms. It is 
possible, therefore, that the first hypothesis is valid, 
although it would be necessary to study many more 
cases to confirm it.
In conclusion, the reported results seem to indicate the 
possibility of identifying, with the brain SPECT, those 
patients who do not respond to therapy, that is, those 
patients who showed a CP unchanged or worsened 
after therapy in the majority of brain regions studied. It 
can be imagined what this possibility means in terms of 
elimination of unnecessary side effects and allocation 
of resources. On the other hand, caution is required 
in evaluating cases with scintigraphic results showing 
reduced or stable CP in a few areas of the brain. Further 
experiments should be conducted in order to interpret 
such cases. In BD, cerebral areas with a worsening of the 
cerebral blood fl ow after therapy have not been found 
and the improvement of perfusion registered with brain 
SPECT reached the highest value observed in the present 
study (5%). This may indicate that this condition could 
be treated more easily.
References
1. Harboe E, Tjensvoll AB, Maroni S, Gøransson LG, Greve OJ, 
Beyer MK, et al. Neuropsychiatric syndromes in patients 
with systemic lupus erythematosus and primary Sjögren 
syndrome: A comparative population-based study. Ann 
Rheum Dis 2009;68:1541-6.
2. Campello Morer I, Velilla Marco J, Hortells Aznar JL, 
Almárcegui Lafi ta C, Barrena Caballo R, Oliveros Juste A. 
Neurological involvement in systemic sclerosis. Rev Clin Esp 
2003;203:373-7.
3. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, 
Hughes GR. Central nervous system involvement in the 
antiphospholipid (Hughes) syndrome. Rheumatology 
(Oxford) 2003;42:200-13.
4. Le Guern V, Belin C, Henegar C, Moroni C, Maillet D, 
Lacau C, et al. Cognitive function and 99mTc ECD brain 
SPECT are signifi cantly correlated in patients with primary 
Sjögren’s Syndrome: A case-control study. Ann Rheum Dis 
2010;69:132-7.
5. Kozora E, Filley CM, Zhang L, Brown MS, Miller DE, 
Arciniegas DB, et al. Immune function and brain abnormalities 
in patients with systemic lupus erythematosus without overt 
neuropsychiatric manifestations. Lupus 2012;21:402-11.
6. Massara A, Bonazza S, Castellino G, Caniatti L, Trotta F, 
Borrelli M, et al. Central nervous system involvement in 
Sjögren’ sindrome: Unusual, but non unremarkable — clinical, 
serological characteristics and outcomes in a large cohort of 
Italian patients. Rheumatology (Oxford) 2010;49:1540-9.
7. Axford JS, Howe FA, Heron C, Griffi ths JR. Sensitivity of 
quantitative (1) H magnetic resonance spectroscopy of the 
brain in detecting early neuronal damage in systemic lupus 
erythematosus. Ann Rheum Dis 2001;60:106-11.
8. Zhang X, Zhu Z, Zhang F, Shu H, Li F, Dong Y. Diagnostic 
value of single-photon-emission computed tomography 
in severe central nervous system involvement of systemic 
lupus erythematosus: A case-control study. Arthritis Rheum 
2005;53:845-9.
9. Lim MK, Suh CH, Kim HJ, Cho YK, Choi SH, Kang JH, 
et al. Systemic lupus erythematosus: Brain MR imaging 
and single-voxel hydrogen 1 MR spectroscopy. Radiology 
2000;217:43-9.
10. Emmi L, Bramati M, De Cristofaro MT, Mascalchi M, Dal 
Pozzo G, Marconi GP, et al. MRI and SPECT investigations of 
the CNS in SLE patients. Clin Exp Rheumatol 1993;11:13-20.
11. Markus HS, Bunker CB, Kouris K, Costa DC, Harrison MJ. 
rCBF abnormalities detected, and sequentially followed, by 
SPECT in neuro-Behçet’s syndrome with normal CT and MRI 
imaging. J Neurol 1992;239:363-6.
12. Mathieu A, Sanna G, Mameli A, Pinna C, Vacca A, Cauli A, 
et al. Sustained normalization of cerebral blood-fl ow after 
iloprost therapy in a patient with neuropsychiatric systemic 
lupus erythematosus. Lupus 2002;11:52-6.
13. Oku K, Atsumi T, Furukawa S, Horita T, Sakai Y, Jodo S, et al. 
Cerebral imaging by magnetic resonance imaging and single 
photon emission computed tomography in systemic lupus 
erythematosus with central nervous system involvement. 
Rheumatology (Oxford) 2003;42:773-7.
14. Baca V, Lavalle C, García R, Catalán T, Sauceda JM, 
Sánchez G, et al. Favorable response to intravenous 
methylprednisolone and cyclophosphamide in children with 
severe neuropsychiatric lupus. J Rheumatol 1999;26:432-9.
15. Liu FY, Huang WS, Kao CH, Yen RF, Wang JJ, Ho ST. 
Usefulness of Tc-99m ECD brain SPECT to evaluate the effects 
of methylprednisolone pulse therapy in lupus erythematosus 
with brain involvement: A preliminary report. Rheumatol Int 
2003;23:182-5.
16. Sun SS, Huang WS, Chen JJ, Chang CP, Kao CH, Wang JJ. 
Evaluation of the effects of methylprednisolone pulse therapy 
in patients with systemic lupus erythematosus with brain 
involvement by Tc-99m HMPAO brain SPECT. Eur Radiol 
2004;14:1311-5.
17. De Cata A, Intiso D, Bernal M, Molinaro F, Mazzoccoli G, 
D’Alessandro V, et al. Prolonged remission of neuro-
Behcet disease following autologous transplantation. Int J 
Immunopathol Pharmacol 2007;20:91-6.
18. Headache Classifi cation Subcommittee of the International 
Headache Society. The International Classification of 
Headache Disorders: 2nd ed. Vol 24. Cephalalgia; 2004. 
p. 1-160.
19. Meusser S, Rubbert A, Manger B, Bock E, Platsch G, Feistel H, 
et al. 99m-Tc-HMPAO-SPECT in diagnosis of early cerebral 
vasculitis. Rheumatol Int 1996;16:37-42.
20. Huang WS, Chiu PY, Tsai CH, Kao A, Lee CC. Objective 
evidence of abnormal regional cerebral blood fl ow in patients 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
Mauro, et al.: Brain SPECT in autoimmune vasculitis
North American Journal of Medical Sciences | Apr 2015 | Volume 7 | Issue 4 |8
with systemic lupus erythematosus on Tc-99m ECD brain 
SPECT. Rheumatol Int 2002;22:178-81.
21. Zayed H, Effat D, Nawito Z, Abdou AA, El Din MN, 
El-Refaei S, et al. Silent central nervous system involvement 
in Egyptian Behçet’s disease patients: Clinical, psychiatric, 
and neuroimaging evaluation. Clin Rheumatol 2011; 
30:1173-80.
22. Driver CB, Wallace DJ, Lee JC, Forbess CJ, Pourrabbani S, 
Minoshima S, et al. Clinical validation of the watershed sign as 
a marker for neuropsychiatric systemic lupus erythematosus. 
Arthritis Rheum 2008;59:332-7.
23. Lass P, Krajka-Lauer J, Homziuk M, Iwaszkiewicz-Bilikiewicz B, 
Koseda M, Hebanowski M, et al. Cerebral blood fl ow in 
Sjögren’s syndrome using 99mTc-HMPAO brain SPET. Nucl 
Med Commun 2000;21:31-5.
24. Lin WY, Wang SJ, Yen TC, Lan JL. Technetium-99m-HMPAO 
brain SPECT in systemic lupus erythematosus with CNS 
involvement. J Nucl Med 1997;38:1112-5.
25. Appenzeller S, Amorim BJ, Ramos CD, Rio PA, de C 
Etchebehere EC, Camargo EE, et al. Voxel-based morphometry 
of brain SPECT can detect the presence of active central 
nervous system involvement in systemic lupus erythematosus. 
Rheumatology (Oxford) 2007;46:467-72.
26. Castellino G, Padovan M, Bortoluzzi A, Borrelli M, Feggi L, 
Caniatti ML, et al. Single photon emission computed 
tomography and magnetic resonance imaging evaluation in 
SLE patients with and without neuropsychiatric involvement. 
Rheumatology (Oxford) 2008;47:319-23.
27. Chuang YW, Hsu CC, Huang YF, Lin HF, Chang CC, Lin CY, 
et al. Brain perfusion SPECT in patients with Behçet’s disease. 
J Neuroradiol 2013;40:288-93.
How to cite this article: We will update details while making issue 
online***
Source of Support: Nil. Confl ict of Interest: None declared.
Author Queries???
AQ1: Please verify the fullform of IQ.
AQ2: Please provide column head.
AQ3: Please check the value.
AQ4: Please check the sentence for missing data.
AQ5: Please provide editable image for Figure 1-5.
AQ6: Please check the sentence for clarity of its meaning.
AQ7: Please confi rm the deletion.
